Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333146 | 0.84 | ALDH1A1 (0.59) | KLK7FPR2KMT2AMEN1MAPT | |
| SCHEMBL8867111 | 0.84 | CYP4F2 (0.62) | KLK7HDAC1HDAC6KMT2AMEN1 | |
| SCHEMBL8867107 | 0.84 | POLB (0.50) | KLK7HDAC1HDAC6KMT2AMEN1 | |
| SCHEMBL4350515 | 0.81 | CNR1 (0.55) | CNR1HDAC1HDAC6KMT2AMEN1 | |
| SCHEMBL5348324 | 0.79 | LOXL2 (0.51) | KLK7KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL15350108 | 0.78 | HDAC1 (0.73) | CNR1HDAC1HDAC6KMT2AMEN1 | |
| SCHEMBL16560992 | 0.78 | KMT2A (0.74) | KLK7CNR1FPR2HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL5348319 | 0.78 | KLKB1 (0.50) | KLK7KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL16128084 | 0.78 | KDM4E (0.60) | KLK7KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL1503956 | 0.78 | TSHR (0.69) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | claimed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | claimed |
| EP-1511718-B1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7053245-B2 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2005-12-22 | — | — | US | disclosed |
| EP-1511718-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | JOLIDON SYNESE | 2004-10-21 | — | — | US | disclosed |
| US-6762320-B2 | MONOAMINE OXIDASE B INHIBITORS; ALZHEIMER'S DISEASE, SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-07-13 | — | — | US | disclosed |
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232883-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | KLK7 4019/4885CNR1 297/4885FPR2 1011/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | KLK7 4170/4885CNR1 1076/4885FPR2 3822/4885 |
| US-20040210079-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, CBR1 | KLK7 4011/4885CNR1 231/4885FPR2 946/4885 |
| US-20050283019-A1 | N-acylamino benzyl ether derivatives | MAOB, MAOA, AOC2 | KLK7 3747/4885CNR1 273/4885FPR2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.